Barry E. Greene - 10 Apr 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
President and CEO, Director
Signature
Brandon Marsh, attorney in fact for Barry E. Greene
Issuer symbol
SAGE
Transactions as of
10 Apr 2025
Net transactions value
-$33,596
Form type
4
Filing time
11 Apr 2025, 16:09:39 UTC
Previous filing
21 Jan 2025
Next filing
29 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +19,964 +23% $0.000000 105,031 10 Apr 2025 Direct F1
transaction SAGE Common Stock Tax liability $33,596 -4,862 -4.6% $6.91 100,169 10 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 57,040 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 19,964 shares.